Skip to main content
Top
Published in: BMC Public Health 1/2022

Open Access 01-12-2022 | Human Papillomavirus | Study protocol

An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics

Authors: Jessica Wells, James L. Klosky, Yuan Liu, Theresa Wicklin Gillespie

Published in: BMC Public Health | Issue 1/2022

Login to get access

Abstract

Background

HPV-related anal cancer occurs in excess rates among people living with HIV (PLWH) and has been increasing in incidence. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV-related disease. Yet, HPV vaccine programs tailored and implemented in the HIV population are lagging for this high-risk group.

Methods

A pre-post intervention study design will be used to tailor, refine, and implement the 4 Pillars™ Practice Transformation Program to increase HPV vaccination among PLWH. Guided by the RE-AIM framework, the CHAMPS study will provide training and motivation to HIV providers and clinic staff to recommend and administer the HPV vaccination within three HIV clinics in Georgia. We plan to enroll 365 HIV participants to receive HPV education, resources, and reminders for HPV vaccination. Sociodemographic, HPV knowledge, and vaccine hesitancy will be assessed as mediators and moderators for HPV vaccination. The primary outcome will be measured as an increase in uptake rate in initiation of the HPV vaccine and vaccine completion (secondary outcome) compared to historical baseline vaccination rate (control).

Discussion

The proposed study is a novel approach to address a serious and preventable public health problem by using an efficacious, evidence-based intervention on a new target population. The findings are anticipated to have a significant impact in the field of improving cancer outcomes in a high-risk and aging HIV population.

Trial registration

NCT05065840; October 4, 2021.
Literature
1.
go back to reference Khandwala P, Singhal S, Desai D, Parsi M, Potdar R. HIV-Associated Anal Cancer Cureus. 2021;13(5):e14834.PubMed Khandwala P, Singhal S, Desai D, Parsi M, Potdar R. HIV-Associated Anal Cancer Cureus. 2021;13(5):e14834.PubMed
2.
go back to reference Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34.CrossRefPubMedPubMedCentral Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34.CrossRefPubMedPubMedCentral
3.
go back to reference De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta analysis. Int J Cancer. 2009;124(7):1626–36.CrossRefPubMed De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta analysis. Int J Cancer. 2009;124(7):1626–36.CrossRefPubMed
4.
go back to reference Shrestha S, Sudenga SL, Smith JS, Bachmann LH, Wilson CM, Kempf MC. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis. 2010;10(1):295.CrossRefPubMedPubMedCentral Shrestha S, Sudenga SL, Smith JS, Bachmann LH, Wilson CM, Kempf MC. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis. 2010;10(1):295.CrossRefPubMedPubMedCentral
5.
go back to reference Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11.CrossRefPubMedPubMedCentral Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11.CrossRefPubMedPubMedCentral
6.
go back to reference Palefsky JM, Gillison ML, Strickler HD. HPV vaccines in immunocompromised women and men. Vaccine. 2006;24:S140–S6.CrossRef Palefsky JM, Gillison ML, Strickler HD. HPV vaccines in immunocompromised women and men. Vaccine. 2006;24:S140–S6.CrossRef
7.
go back to reference Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735–44.CrossRefPubMedPubMedCentral Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735–44.CrossRefPubMedPubMedCentral
8.
go back to reference Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246–53.CrossRefPubMed Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246–53.CrossRefPubMed
9.
go back to reference Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.CrossRefPubMed Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.CrossRefPubMed
10.
go back to reference Meites E, Markowitz LE, Paz-Bailey G, Oster AM, Group NS. HPV vaccine coverage among men who have sex with men–national HIV behavioral surveillance system, United States, 2011. Vaccine. 2014;32(48):6356–9.CrossRef Meites E, Markowitz LE, Paz-Bailey G, Oster AM, Group NS. HPV vaccine coverage among men who have sex with men–national HIV behavioral surveillance system, United States, 2011. Vaccine. 2014;32(48):6356–9.CrossRef
11.
go back to reference Cummings T, Kasting ML, Rosenberger JG, Rosenthal SL, Zimet GD, Stupiansky NW. Catching up or missing out? Human papillomavirus vaccine acceptability among 18- to 26-year-old men who have sex with men in a US National Sample. Sex Transm Dis. 2015;42(11):601–6.CrossRefPubMed Cummings T, Kasting ML, Rosenberger JG, Rosenthal SL, Zimet GD, Stupiansky NW. Catching up or missing out? Human papillomavirus vaccine acceptability among 18- to 26-year-old men who have sex with men in a US National Sample. Sex Transm Dis. 2015;42(11):601–6.CrossRefPubMed
12.
go back to reference Nadarzynski T, Smith H, Richardson D, Pollard A, Llewellyn C. Perceptions of HPV and attitudes towards HPV vaccination amongst men who have sex with men: a qualitative analysis. Br J Health Psychol. 2017;22(2):345–61.CrossRefPubMed Nadarzynski T, Smith H, Richardson D, Pollard A, Llewellyn C. Perceptions of HPV and attitudes towards HPV vaccination amongst men who have sex with men: a qualitative analysis. Br J Health Psychol. 2017;22(2):345–61.CrossRefPubMed
13.
go back to reference Reiter PL, Brewer NT, McRee A-L, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis. 2010;37(3):197.CrossRefPubMedPubMedCentral Reiter PL, Brewer NT, McRee A-L, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis. 2010;37(3):197.CrossRefPubMedPubMedCentral
14.
go back to reference FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old [press release]. 2018. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old [press release]. 2018.
15.
go back to reference Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(5):1–30.PubMed Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(5):1–30.PubMed
16.
go back to reference Abdool Karim SS, Passmore JS, Baxter C. The microbiome and HIV prevention strategies in women. Curr Opin HIV AIDS. 2018;13(1):81–7.CrossRefPubMed Abdool Karim SS, Passmore JS, Baxter C. The microbiome and HIV prevention strategies in women. Curr Opin HIV AIDS. 2018;13(1):81–7.CrossRefPubMed
17.
go back to reference Nowalk MP, Moehling KK, Zhang S, Raviotta JM, Zimmerman RK, Lin CJ. Using the 4 pillars™ to increase vaccination among high-risk adults: who benefits? Am J Manag Care. 2017;23(11):651.PubMedPubMedCentral Nowalk MP, Moehling KK, Zhang S, Raviotta JM, Zimmerman RK, Lin CJ. Using the 4 pillars™ to increase vaccination among high-risk adults: who benefits? Am J Manag Care. 2017;23(11):651.PubMedPubMedCentral
18.
go back to reference Zimmerman RK, Brown AE, Pavlik VN, Moehling KK, Raviotta JM, Lin CJ, et al. Using the 4 pillars practice transformation program to increase pneumococcal immunizations for older adults: a cluster-randomized trial. J Am Geriatr Soc. 2017;65(1):114–22.CrossRefPubMed Zimmerman RK, Brown AE, Pavlik VN, Moehling KK, Raviotta JM, Lin CJ, et al. Using the 4 pillars practice transformation program to increase pneumococcal immunizations for older adults: a cluster-randomized trial. J Am Geriatr Soc. 2017;65(1):114–22.CrossRefPubMed
19.
go back to reference Zimmerman RK, Moehling KK, Lin CJ, Zhang S, Raviotta JM, Reis EC, et al. Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 pillars™ practice transformation program. Vaccine. 2017;35(1):109–17.CrossRefPubMed Zimmerman RK, Moehling KK, Lin CJ, Zhang S, Raviotta JM, Reis EC, et al. Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 pillars™ practice transformation program. Vaccine. 2017;35(1):109–17.CrossRefPubMed
20.
go back to reference Zimmerman RK, Raviotta JM, Nowalk MP, Moehling KK, Reis EC, Humiston SG, et al. Using the 4 pillars™ practice transformation program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination. Vaccine. 2017;35(45):6180–6.CrossRefPubMedPubMedCentral Zimmerman RK, Raviotta JM, Nowalk MP, Moehling KK, Reis EC, Humiston SG, et al. Using the 4 pillars™ practice transformation program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination. Vaccine. 2017;35(45):6180–6.CrossRefPubMedPubMedCentral
21.
go back to reference Apaydin KZ, Fontenot HB, Shtasel D, Dale SK, Borba CP, Lathan CS, et al. Facilitators of and barriers to HPV vaccination among sexual and gender minority patients at a Boston community health center. Vaccine. 2018;36(26):3868–75.CrossRefPubMedPubMedCentral Apaydin KZ, Fontenot HB, Shtasel D, Dale SK, Borba CP, Lathan CS, et al. Facilitators of and barriers to HPV vaccination among sexual and gender minority patients at a Boston community health center. Vaccine. 2018;36(26):3868–75.CrossRefPubMedPubMedCentral
22.
go back to reference Gorbach PM, Cook R, Gratzer B, Collins T, Parrish A, Moore J, et al. Human papillomavirus vaccination among young men who have sex with men and transgender women in 2 US cities, 2012–2014. Sex Transm Dis. 2017;44(7):436.CrossRefPubMedPubMedCentral Gorbach PM, Cook R, Gratzer B, Collins T, Parrish A, Moore J, et al. Human papillomavirus vaccination among young men who have sex with men and transgender women in 2 US cities, 2012–2014. Sex Transm Dis. 2017;44(7):436.CrossRefPubMedPubMedCentral
23.
go back to reference Klosky JL, Hudson MM, Chen Y, Connelly JA, Wasilewski-Masker K, Sun C-L, et al. Human papillomavirus vaccination rates in young cancer survivors. J Clin Oncol. 2017;35(31):3582.CrossRefPubMedPubMedCentral Klosky JL, Hudson MM, Chen Y, Connelly JA, Wasilewski-Masker K, Sun C-L, et al. Human papillomavirus vaccination rates in young cancer survivors. J Clin Oncol. 2017;35(31):3582.CrossRefPubMedPubMedCentral
24.
go back to reference Reiter PL, Katz ML, Bauermeister JA, Shoben AB, Paskett ED, McRee A-L. Recruiting young gay and bisexual men for a human papillomavirus vaccination intervention through social media: the effects of advertisement content. JMIR Public Health Surveill. 2017;3(2):e33.CrossRefPubMedPubMedCentral Reiter PL, Katz ML, Bauermeister JA, Shoben AB, Paskett ED, McRee A-L. Recruiting young gay and bisexual men for a human papillomavirus vaccination intervention through social media: the effects of advertisement content. JMIR Public Health Surveill. 2017;3(2):e33.CrossRefPubMedPubMedCentral
25.
go back to reference Subasinghe AK, Nguyen M, Wark JD, Tabrizi SN, Garland SM. Targeted Facebook advertising is a novel and effective method of recruiting participants into a human papillomavirus vaccine effectiveness study. JMIR Res Protocols. 2016;5(3):e154.CrossRef Subasinghe AK, Nguyen M, Wark JD, Tabrizi SN, Garland SM. Targeted Facebook advertising is a novel and effective method of recruiting participants into a human papillomavirus vaccine effectiveness study. JMIR Res Protocols. 2016;5(3):e154.CrossRef
26.
go back to reference Wells JS, Flowers L, Paul S, Nguyen ML, Sharma A, Holstad M. Knowledge of anal cancer, anal cancer screening, and hpv in hiv-positive and high-risk hiv-negative women. J Cancer Educ. 2020;35(3):606–15.CrossRefPubMed Wells JS, Flowers L, Paul S, Nguyen ML, Sharma A, Holstad M. Knowledge of anal cancer, anal cancer screening, and hpv in hiv-positive and high-risk hiv-negative women. J Cancer Educ. 2020;35(3):606–15.CrossRefPubMed
27.
go back to reference York JM, Klosky JL, Chen Y, Connelly JA, Wasilewski-Masker K, Giuliano AR, et al. Patient-level factors associated with lack of health care provider recommendation for the human papillomavirus vaccine among young Cancer survivors. J Clin Oncol. 2020;38(25):2892–901.CrossRefPubMedPubMedCentral York JM, Klosky JL, Chen Y, Connelly JA, Wasilewski-Masker K, Giuliano AR, et al. Patient-level factors associated with lack of health care provider recommendation for the human papillomavirus vaccine among young Cancer survivors. J Clin Oncol. 2020;38(25):2892–901.CrossRefPubMedPubMedCentral
28.
go back to reference Rand CM, Vincelli P, Goldstein NP, Blumkin A, Szilagyi PG. Effects of phone and text message reminders on completion of the human papillomavirus vaccine series. J Adolesc Health. 2017;60(1):113–9.CrossRefPubMed Rand CM, Vincelli P, Goldstein NP, Blumkin A, Szilagyi PG. Effects of phone and text message reminders on completion of the human papillomavirus vaccine series. J Adolesc Health. 2017;60(1):113–9.CrossRefPubMed
29.
go back to reference Hox JJ, Moerbeek M. Van de Schoot R. multilevel analysis: techniques and applications: Routledge; 2017.CrossRef Hox JJ, Moerbeek M. Van de Schoot R. multilevel analysis: techniques and applications: Routledge; 2017.CrossRef
30.
go back to reference Georgia Department of Health. HIV surveillance summary, Georgia 2018. In: Section HAE, editor. 2020. Georgia Department of Health. HIV surveillance summary, Georgia 2018. In: Section HAE, editor. 2020.
31.
go back to reference Panel PsC. HPV vaccination for cancer prevention: progress, opportunities, and a renewed call to action. A report to the president of the United States from the chair of the President’s Cancer Panel 2018. Panel PsC. HPV vaccination for cancer prevention: progress, opportunities, and a renewed call to action. A report to the president of the United States from the chair of the President’s Cancer Panel 2018.
Metadata
Title
An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics
Authors
Jessica Wells
James L. Klosky
Yuan Liu
Theresa Wicklin Gillespie
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2022
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-022-14100-0

Other articles of this Issue 1/2022

BMC Public Health 1/2022 Go to the issue